Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Spanish scientists discover melatonin consumption helps control weight gain

Melatonin is a natural hormone segregated by the body and melatonin levels generally increase in the dark at night. It is also found in fruit and vegetables like mustard, Goji berries, almonds, sunflower seeds, cardamom, fennel, coriander and cherries.

26 Sep 2013

Being overweight but metabolically healthy is not linked with increased risk of heart attack

Metabolically healthy women have the same cardiovascular disease risk regardless of their BMI, according to research presented at the ESC Congress today by Dr S-ren Sk-tt Andersen and Dr Michelle Schmiegelow from Denmark.

2 Sep 2013

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease in patients with mild dyslipidemia.

30 Aug 2013

Many women die due to Cad, yet less likely to receive preventive recommendations

Despite coronary artery disease (CAD) killing at least as many women as men each year, women are still today less likely to receive preventive recommendations, such as lipid-lowering therapy, aspirin, and lifestyle advice, than are men at a similar risk level.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to prevent the deadly parasitic disease.

26 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Study: Heart disease emerges as number one killer among Indians

Heart disease has emerged as the number one killer among Indians, according to a recent study by the Registrar General of India ( RGI) and the Indian Council of Medical Research (ICMR).

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.

22 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Epanova™ for the treatment for patients with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500mg/dL).

9 Jul 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Weight-loss surgery may improve metabolic risk factors in obese patients: Study

Among mild to moderately obese patients with type 2 diabetes, adding gastric bypass surgery to lifestyle and medical management was associated with a greater likelihood of improved levels of metabolic risk factors such as blood glucose, LDL-cholesterol and systolic blood pressure, according to a study in the June 5 issue of JAMA.

5 Jun 2013

Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, announced three poster presentations at the National Lipid Association annual meeting held in Las Vegas, Nevada, May 30- June 2, 2013, as well as a Synageva-sponsored satellite symposium held on Friday, May 31, 2013.

1 Jun 2013

Omthera to be acquired by AstraZeneca

AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.

28 May 2013

Study explains gender differences in the impact of OSA on cardiovascular disease, mortality

A new study from researchers in Japan indicates that obstructive sleep apnea is independently associated with visceral (abdominal) fat accumulation only in men, perhaps explaining gender differences in the impact of OSA on cardiovascular disease and mortality.

23 May 2013

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

21 May 2013

FDA approves Mylan's ANDA for Fenofibrate Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg.

17 May 2013

Dyslipidemia News and Research

Spanish scientists discover melatonin consumption helps control weight gain

Being overweight but metabolically healthy is not linked with increased risk of heart attack

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Many women die due to Cad, yet less likely to receive preventive recommendations

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Study: Heart disease emerges as number one killer among Indians

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Omthera submits Epanova NDA to FDA for treatment of severe hypertriglyceridemia

Eisai submits BELVIQ NDS with Health Canada

Weight-loss surgery may improve metabolic risk factors in obese patients: Study

Synageva BioPharma presents data on cholesteryl ester storage disease at NLA annual meeting

Omthera to be acquired by AstraZeneca

Study explains gender differences in the impact of OSA on cardiovascular disease, mortality

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

FDA approves Mylan's ANDA for Fenofibrate Tablets

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News